View Single Post
Old 10-24-2019, 09:09 PM
Suebee Suebee is offline
MS Master
Join Date: Mar 2015
Location: Houston, TX
Posts: 525

I am really confused as to why the HDL/MS slowing disease progression connection is being studied in the context of a dmd. Is this because there is no money in studying how fish oil supplements (which increase HDL) can slow MS so scientists instead are looking to find a pharmaceutical way to increase HDL??? Have I missed something here?
For many years now, Fatty acid supplementation has been thought to slow MS progression based “ largely . . . on early research which showed that omega-3 could inhibit a certain protein (called matrix metalloproteinase-9) known to trigger inflammation in the [CNS]”

And Dr Swank, a.k.a The Swank Diet, developed over 40 years ago, connected good fats ( cod liver oil or fish oil) to reduced MS disability. Dr. Wahls writes” Swank believed MS had a vascular component... His diet is consistent with the cholesterol hypothesis of atherosclerosis that suggests saturated fat has deleterious effect on cerebrovascular health....Recent studies by other investigators found positive associations between worsening disability and total cholesterol and triglycerides levels and negative associations between HDL cholesterol and disability status of pwMS...”.

Further, Dr. Wahls’ diet “The WahlsElim diet encourages use of avocado, olive, sesame and sunflower oils which are sources of monounsaturated fatty acids. Flax, walnut and hemp oils are also encouraged as a source of alpha-linolenic acid, an essential fatty acid, but amounts are limited to two tablespoons per day to maintain balance in omega 6:3 ratio. Higher alpha-linolenic acid intake was associated with reduced risk of MS in the Nurses’ Health Study.”

So why exactly is fingloid being studied to its connection to HDL? Maybe I’m missing something.
Reply With Quote